April 20, 2014 11:11 PM ET

Healthcare Equipment and Supplies

Company Overview of Kensey Nash Corporation

Company Overview

Kensey Nash Corporation, a medical device company, engages in the field of regenerative medicine products and technologies to help repair damaged or diseased tissues. The company involves in designing, developing, manufacturing, and processing proprietary medical devices, including resorbable biomaterial products, such as synthetic polymers and collagen. It provides various orthopaedic market products comprising soft tissue and bone fixation products for the fixation and repair of musculoskeletal tissues; and bone void fillers and scaffolds. The company also offers cardiovascular market products that include original Angio-Seal device, a vascular closure device; general surgery market produc...

735 Pennsylvania Drive

Exton, PA 19341

United States

Founded in 1984

307 Employees





Key Executives for Kensey Nash Corporation

Chief Executive Officer
Age: 61
Age: 78
Chief Financial Officer
Age: 54
Chief Operating Officer and Assistant Secretary
Age: 49
Vice President of Legal Affairs
Compensation as of Fiscal Year 2013.

Kensey Nash Corporation Key Developments

Kensey Nash Corporation Announces Amendments to its Bylaws; Announces Board Changes

On May 2, 2012, Kensey Nash Corporation entered into an agreement and plan of merger with Koninklijke DSM N.V. and Biomedical Acquisition Corporation. Pursuant to the terms and subject to the conditions of the merger agreement, at 3:00 p.m. ET on June 22, 2012, Biomedical Acquisition Corporation filed a certificate of merger with the Secretary of State of the State of Delaware. Pursuant to the certificate of merger, Biomedical Acquisition Corporation merged with and into Kensey Nash, effective as of 11:59 p.m. ET on June 22, 2012 (Effective Time), in accordance with the short-form merger provisions available under Delaware law, which allow the completion of the merger without a vote or meeting of stockholders of Kensey Nash. Also pursuant to the merger agreement, at the effective time, Kensey Nash's bylaws were amended and restated in their entirety to be identical to the bylaws of Biomedical Acquisition Corporation, as in effect immediately prior to the effective time, except that the name of the company set forth therein is Kensey Nash Corporation. Effective as of the effective time, each of Joseph W. Kaufmann, Douglas G. Evans, P.E., C. McCollister Evarts, M.D., Robert J. Bobb, Donald E. Morel, Jr., Ph.D., Walter R. Maupay, Jr. and Lisa D. Earnhardt no longer serve on the Board of Directors of Kensey Nash nor any committees of the Board on which they served. Pursuant to the merger agreement, Chistophe Dardel and Hugh C. Welsh became the sole directors of Kensey Nash as of the effective time.

Kensey Nash Corporation(NasdaqGM:KNSY) dropped from Russell 2000 Index

Kensey Nash Corporation will be removed from Russell 2000 Index.

Kensey Nash Corporation(NasdaqGM:KNSY) dropped from Russell 3000 Index

Kensey Nash Corporationwill be removed from Russell 3000 Index.

Similar Private Companies By Industry

Company Name Region
Mekanika, Inc. United States
CertiChem, Inc. United States
KCI Animal Health LLC United States
SourceMark, LLC United States
Invetech, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Kensey Nash Corporation, please visit www.kenseynash.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.